Tuesday, June 16, 2026

North Korea Condemns Ideological and Cultural Infiltration as Imperialist ‘Flexible Warfare’ Tactic

North Korea warns of Western imperialist strategies targeting youth through cultural infiltration, claiming it destabilizes their regime.

Trump Media Stock Faces Wild Swings Amid Election Tension

Donald Trump's DJT stock saw fluctuations, closing down 1.16% after a volatile trading day amid election dynamics.

San Diego Padres Shortstop Kim Ha Seong Stays Hot in Atlanta Doubleheader

Major League Baseball (MLB) San Diego Padres...

Tag: Japan

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

CARTISTEM vs. Traditional Treatments: What Makes Medipost’s Stem Cell Therapy a Game-Changer?

Medipost to commercialize CARTISTEM in Japan using domestically produced media, enhancing supply chain stability and competitiveness.

U.S., Japan and China Advance Stem Cell Commercialization While Korea Works to Close Gaps

The global stem cell therapy market is rapidly growing, but South Korea faces challenges in commercialization compared to the U.S. and Japan.

Medipost Reports Positive Phase 3 Results for CARTISTEM in Japan’s Knee Osteoarthritis Trial

Medipost's CARTISTEM therapy shows significant efficacy in Phase 3 trials for knee osteoarthritis in Japan, enhancing global competitiveness.

Celltrion Launches New Autoimmune Drug Avtozma in Japan

Celltrion launches Avtozma for autoimmune diseases in Japan, expanding its product portfolio and strengthening market presence.

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

Neurophet Unveils AI-Powered Alzheimer’s Treatment Software at ITEM 2026 in Japan

Neurophet showcases AI-driven brain disease tech at ITEM 2026 in Japan, partnering with Hokuyaku Takeyama to expand market reach.

Celltrion’s Breakthrough: Why Vegzelma and Herzuma Lead in Japan’s Oncology Market

Celltrion's cancer treatments dominate the Japanese market, with Vegzelma and Herzuma capturing significant shares, showcasing strong growth.

How Celltrion’s Herceptin Biosimilar Herzuma Achieved 74% Market Share in Japan: A Game Changer for Cancer Treatment

Celltrion's Herzuma biosimilar captures 74% of Japan's trastuzumab market, enhancing patient access and leveraging favorable policies.

Medipost’s CARTISTEM® Completes Phase 3 Trials in Japan: What This Means for Knee Osteoarthritis Treatment

Medipost completes Phase 3 trial for CARTISTEM in Japan, targeting knee osteoarthritis treatment and planning U.S. trial enrollment soon.

What Makes DOOTH the Game-Changer in Absorbable Sutures? Discover Its Unique Advantages!

CGBio is expanding its aesthetic business by exporting the absorbable suture DOOTH to Japan, aiming for global recognition and regulatory approvals.

Hemlibra Breakthrough: 91% of Hemophilia Patients in Japan Experience No Adverse Reactions!

JW Pharmaceutical's Hemlibra shows 91% safety in Japanese hemophilia patients, with no adverse reactions in long-term study.

GCCell Secures Groundbreaking Patent for Next-Gen Cell Therapy: What It Means for the Future of Immunotherapy

GC Cell has completed the registration of core technology patents for next-gen cell and gene therapies in South Korea and Japan.

Korean Spine-Implant Maker Targets Japan: L&K Biomed Showcases BluEX-LT at the Scoliosis Research Society Meeting

L&K Biomed showcased its products at the SRS conference in Japan, aiming to expand its market share in the APAC region, especially Japan.

Samsung Biologics Targets Japan’s $12.3 Billion CDMO Market: What You Need to Know

Samsung Biologics expands in Japan, targeting top pharma firms with new CMO brand 'ExellenS' and enhancing production capabilities.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.